KFGK
RXRX icon

Keystone Financial Group (Kentucky)’s Recursion Pharmaceuticals RXRX Stock Holding History

Keystone Financial Group (Kentucky)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.1K Buy
16,000
+2,000
+14% +$7.73K ﹤0.01% 513
2025
Q4 		$57.3K Buy
+14,000
New +$69.3K ﹤0.01% 447

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Keystone Financial Group (Kentucky)'s RXRX Position: Q1 2026 in Review

Keystone Financial Group (Kentucky) increased its Recursion Pharmaceuticals (RXRX) stake by 14% in Q1 2026, buying an estimated $7.73K and bringing the position to 16,000 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #513.

Keystone Financial Group (Kentucky) first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $57.3K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Keystone Financial Group (Kentucky) held 16,000 shares of Recursion Pharmaceuticals worth $49.1K as of Q1 2026.
  • Keystone Financial Group (Kentucky) bought 2,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $7.73K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Keystone Financial Group (Kentucky)'s portfolio in Q1 2026, its #513 holding.
  • Keystone Financial Group (Kentucky) first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Keystone Financial Group (Kentucky)'s Recursion Pharmaceuticals position peaked at $57.3K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Keystone Financial Group (Kentucky)'s 13F filing for Q1 2026, filed 13 May 2026.